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Abstract
Background
Behavioral variant frontotemporal dementia (bvFTD) has profound
consequences on patients and their families. In this multicenter study,
we investigated the contribution of cognitive and neuropsychiatric
factors to everyday function at diﬀerent levels of overall functional
impairment.
Methods
In a retrospective cross-sectional study, 109 patients with bvFTD from 4
specialist frontotemporal dementia centers (Australia, England, India,
and Brazil) were included. The measures administered evaluated ev-
eryday function (Disability Assessment for Dementia [DAD]), de-
mentia staging (Clinical Dementia Rating [CDR]), general cognition
(Addenbrooke’s Cognitive Examination–revised [ACE-R]), and neu-
ropsychiatric symptoms (Neuropsychiatric Inventory [NPI]). Patients
were then subdivided according to functional impairment on the DAD
into mild, moderate, severe, and very severe subgroups. Three separate
multiple linear regression analyses were run, where (1) total DAD, (2) basic activities of daily living
(BADL), and (3) instrumental activities of daily living (IADL) scores were dependent variables;
ACE-R total score and selectedNPI domains (agitation/aggression, euphoria, apathy, disinhibition,
irritability, aberrant motor behavior) were used as independent variables. Age, sex, education, and
country of origin were controlled for in the analyses.
Results
Cognitive deﬁcits were similar across the mild, moderate, and severe subgroups but signiﬁcantly
worse in the very severe subgroup. NPI domain scores (agitation/aggression, euphoria, apathy,
disinhibition, irritability, aberrant motor behavior) did not diﬀer across the DAD subgroups. In
the multiple regression analyses, a model including ACE-R and NPI apathy explained 32.5% of
the variance for total DAD scores. For IADL, 35.6% of the variance was explained by the ACE-R
only. No model emerged for BADL scores.
Conclusions
Cognitive deﬁcits and apathy are key contributors to functional disability in bvFTD but factors
underlying impairment in BADLs remain unclear. Treatments targeting reduction of disability need
to address apathy and cognitive impairment to ensure greater eﬃcacy, especially in regards to IADLs.
Neurology Department (MSY, TBLdS, VSB, SMDB, RN), University of São Paulo, Brazil; Ageing, Work & Health Research Unit (CMO), Faculty of Health Sciences, University of Sydney,
Australia; Nizam’s Institute of Medical Sciences (SM, SA), Hyderabad, India; Cognitive and Behavioral Neurology Research Group (VA-C, HCG, PC), Faculdade deMedicina and Hospital
das Cl´ınicas, Universidade Federal de Minas Gerais, Belo Horizonte; Department of Neurology (MLFB, BD), University of Campinas, São Paulo, Brazil; ARC Centre of Excellence in
Cognition and its Disorders (JRH, OP, EM), University of New SouthWales; Neuroscience Research Australia (JRH, OP), Randwick; and School of Health Sciences (EM), University of East
Anglia, Norwich, UK.
At the time of the data collection, SA and SM were based at Nizam’s Institute of Medical Sciences, Hyderabad, India; EM, OP, JRH were based at Neuroscience Research Australia.
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at
Neurology.org/cp.
120 Copyright © 2018 American Academy of Neurology
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Behavioral variant frontotemporal dementia (bvFTD) has
profound consequences on the lives of patients and their
families.1-3 Marked behavioral and cognitive deﬁcits are
present from early in the disease4 and underlie the marked
functional changes observed throughout the disease course.
It is not surprising, therefore, that bvFTD is associated with
higher rates of caregiver distress5,6 and burden7,8 than other
forms of dementia.
Functional impairment is signiﬁcantly more marked in
bvFTD than other frontotemporal dementia (FTD)
variants1,9 and Alzheimer disease, even when matched for
disease duration. Functional disability may also predict dis-
ease progression in bvFTD.10 For these reasons, more gen-
eralizable understanding of factors underlying disability in
bvFTD is required to provide evidence for planning of
interventions, clinical decisions, and other areas of family life.
Although it has been demonstrated that apathy and cognitive
scores are associated with functional decline in bvFTD,9-11
the speciﬁc contributions of these variables to basic activities
of daily living (BADL) and instrumental activities of daily
living (IADL) are unknown, as large group studies including
well-characterized bvFTD samples are rare. This study takes
advantage of this multicenter initiative to apply a quantitative
approach that can be generalized across countries.
The objectives of the present study were to (1) investigate
the cognitive and neuropsychiatric proﬁles of patients with
bvFTD according to diﬀerent levels of functional impairment
in a large group of patients seen across 4 international spe-
cialist centers; and (2) explore whether cognitive deﬁcits or
neuropsychiatric symptoms are directly associated with
functional impairment in activities of daily living (ADL) in
bvFTD.
Methods
Participants
This is a retrospective cross-sectional study resulting from
the secondary analysis of data from studies run at collabo-
rating centers. In total, 109 patients diagnosed with bvFTD
according to international criteria12,13 were included from 4
research centers: Australia, Frontier–Frontotemporal De-
mentia Research Centre (Sydney); Brazil, Cognitive and
Behavioral Neurology Group (GNCC-SP) and Old Age
Research Group (PROTER) at the University of São Paulo,
and Cognitive and Behavioral Neurology Group (GNCC-
MG) at the Federal University of Minas Gerais and the
Neuropsychology and Dementia Unit of the Department of
Neurology at the State University of Campinas (UNI-
CAMP); England, Early Onset Dementia Clinic at the
University of Cambridge; India, Nizam’s Institute of Medical
Sciences, Hyderabad. Samples were as follows: Australia (n =
45), Brazil (n = 31), England (n = 15), and India (n = 18).
Patients were diagnosed by experienced neurologists or psy-
chiatrists and diagnosis was based on clinical and cognitive
assessments and multidisciplinary consensus, as well as struc-
tural neuroimaging. Inclusion criteria for patients were age >40
years, education >2 years, and presence of an informant who
was involved in the daily routine of the patient (formal or
informal carer; usually spending more than 8 h/d with the
patient). Individuals with visual, auditory, or motor deﬁcits
preventing them from understanding instructions or perform-
ing cognitive tasks; other uncontrolled clinical diseases (such as
hypertension and diabetes); serious and debilitating psychiatric
disorders such as major depression, schizophrenia, or bipolar
disorder; clinical evidence or neuroimaging examination ﬁnd-
ings suggestive of vascular problems; or dementias or etiologies
other than FTD were excluded.
Instruments
Sociodemographic and clinical variables were recorded at all
centers, including age, years of formal education, marital
status, and presence of other clinical conditions.
Functional disability
The Disability Assessment for Dementia (DAD)14 was used
to evaluate functional impairment, and was administered to
all caregivers during an interview. It includes 40 items that
assess BADL and IADL. To avoid sex bias, questions that do
not apply to patients (e.g., cooking, house chores, ﬁnances)
are excluded from the total score. Separate total and BADL
and IADL subscores are computed. Scores vary from 0 to 100
and higher scores indicate better performance. A percentage
score, as an index of functional preservation, takes into ac-
count the premorbid state of the patient, as it does not
consider the tasks never performed before.
Dementia staging
To determine dementia staging, the Clinical Dementia Rat-
ing (CDR) scale15 was completed. A predeﬁned algorithm
allows the calculation of a total score, with 0 indicating
preserved performance, 0.5 mild impairment, 1.0 mild de-
mentia, 2.0 moderate dementia, and 3.0 severe dementia.
General cognitive status
The Addenbrooke’s Cognitive Examination–revised (ACE-
R)16 consists of a brief cognitive assessment battery testing 5
diﬀerent cognitive domains. The highest score is 100 points,
and higher scores indicate better performance.
This is a retrospective cross-sectional
study resulting from the secondary
analysis of data from studies run at
collaborating centers.
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Neuropsychiatric symptoms
The Neuropsychiatric Inventory17 (NPI) in its short version
is a 10-item questionnaire that assesses the frequency and
severity of neuropsychiatric and behavioral symptoms. For
the present study, we included scores for agitation/
aggression, euphoria, apathy, disinhibition, irritability, and
aberrant motor behavior (maximum score per domain is 12).
These represent the behavioral disturbances that are most
frequently observed among patients with bvFTD.5,18-20 The
English subsample did not have scores for the NPI assess-
ment. To avoid excluding the English subsample from the
descriptive analyses, scores for the NPI subdomains were
input using the method of multiple imputations described by
Rubin,21 using linear regressions.
Data analyses
The χ2 test was used to compare categorical variables be-
tween the diagnostic groups. The Kolmogorov-Smirnov test
determined the absence of normal distribution in most of the
continuous variables; therefore, nonparametric tests were
applied. Dispersion and position indices are presented by
means of interquartile ranges, such that the ﬁrst quartile
(Q1) represents percentile 25, the median (MD or Q2) is
percentile 50, and the third quartile (Q3) represents per-
centile 75.
Between-group analyses (diﬀerent levels of functional
impairment in the DAD) were conducted with the Kruskal-
Wallis test. For the investigation of the inﬂuence of neuro-
psychiatric symptoms and cognitive changes at diﬀerent
levels of functional impairment, the sample was categorized
on the basis of DAD scores as mild (76–100), moderate
(51–75), severe (26–50), and very severe (0–25).1 For these
analyses, considering a moderate eﬀect size (0.3), the present
sample (n = 109) generated 72% of power (moderate).
Multiple linear regression analyses21 were performed with DAD
total score, BADL, and IADL scores as numerical dependent
variables, andACE-R total score, agitation/aggression, euphoria,
apathy, disinhibition, irritability, and aberrant motor behavior
(NPI subscores) as independent variables, controlling for age,
sex, years of education, and country. For the regression analyses,
the sample from England was excluded, as we did not have NPI
scores available. For statistical analysis, SPSS v.17.0 and Statis-
tica v.7.0 were used.
Standard protocol approvals, registrations,
and patient consents
Studies were approved by the local ethics committee at each
research center. Informed consent was obtained from patients
or caregivers.
Results
Patients from the 4 centers were matched for age, sex,
education, and CDR scores. Patients from India had
signiﬁcantly lower cognitive ACE-R scores compared
with patients from Australia and England. Functional
scores (total DAD) did not diﬀer among the countries.
However, there were signiﬁcant diﬀerences for BADL and
IADL subscores. For BADL scores, the sample from Brazil
had signiﬁcantly lower scores than the samples in Australia
and England. For IADL scores, the sample from India had
lower scores than the samples in Brazil and England
(table 1).
Cognitive and behavioral profiles: Mild,
moderate, severe, and very severe scores on
the DAD
We stratiﬁed the sample by levels of functional impairment
on the DAD to compare cognitive and behavioral proﬁles
according to level of functional impairment. As shown in
table 2, demographic characteristics did not diﬀer across the
subgroups. The only exception was the moderate DAD
subgroup, which contained a greater proportion of men
compared to other DAD subgroups.
There was an overall signiﬁcant group eﬀect for degree of
cognitive impairment across the subgroups. Cognitive
deﬁcits, as measured by the ACE-R, were similar for DAD
score ranges mild, moderate, and severe (table 2 and ﬁgure,
A), where cognitive scores seemed to be on a plateau and
relatively high (mean ;67/100). Cognitive scores were
signiﬁcantly lower in the very severe subgroup (mean
40/100) in comparison to the other DAD score subgroups
(p < 0.001).
In regards to neuropsychiatric symptoms (NPI domains),
there were no signiﬁcant diﬀerences in NPI domain scores
(agitation/aggression, euphoria, apathy, disinhibition, irri-
tability, aberrant motor behavior) across the subgroups
(table 2 and ﬁgure, B).
Are cognitive deficits or neuropsychiatric
symptoms underlying functional disability?
To investigate the inﬂuence of the diﬀerent variables on
functional disability, 3 separate multiple linear regression
analyses were performed. The dependent variables were (1)
total DAD, (2) BADL, and (3) IADL scores. ACE-R total
score, agitation/aggression, euphoria, apathy, disinhibition,
irritability, and aberrant motor behavior (NPI subscores)
were included in the model as independent variables.
Results were controlled for age, sex, years of education, and
country.
A total of 32.5% of the variance on total DAD scores was
explained by a model containing ACE-R and apathy. No
model emerged to explain the variance of BADL scores. For
IADL scores, 35.6% of the variance was explained by a model
combining ACE-R only (table 3). The remaining NPI vari-
ables and demographic characteristics did not make an im-
portant contribution to the 3 models.
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Table 1 Sociodemographic and clinical characteristics of the sample divided by country of origin
Variables
Total,
n = 109
Countries
p Value
Australia, n = 45 Brazil, n = 31 England, n = 15 India, n = 18
Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3
Age, y 60.00 66.00 71.00 60.00 68.00 73.00 61.00 65.00 72.00 58.00 64.00 67.00 55.00 62.00 69.00 0.155
Sex, n (%)
Male 70 (64.22) 28 (62.22) 19 (61.29) 14 (93.33) 9 (50.00)
Female 38 (34.86) 16 (35.56) 12 (38.71) 1 (6.67) 9 (50.00) 0.075
Education, y 9.00 11.00 15.00 9.00 11.00 13.00 4.00 8.00 15.00 10.00 11.00 13.00 10.00 12.00 15.00 0.123
CDR 1.00 1.00 2.00 1.00 1.00 1.00 1.00 1.00 2.00 1.00 1.00 1.00 1.00 2.00 2.00 0.176
ACE-R (max 100) 51.00 66.00 79.00 63.00 72.00 83.00 51.00 58.00 73.00 62.00 81.00 87.00 3.00 22.00 62.00 <0.001a
DAD total 27.00 47.50 65.00 27.00 49.00 67.00 35.00 45.00 60.00 41.00 56.00 81.00 7.00 25.50 54.00 0.099
DAD BADL 40.00 55.00 76.00 43.00 70.00 82.00 40.00 50.00 55.00 58.00 64.00 82.00 17.00 43.50 88.00 0.014b
DAD IADL 15.00 35.00 60.00 13.00 34.00 53.00 20.00 40.00 60.00 31.00 50.00 80.00 5.00 18.50 26.00 0.002c
Abbreviations: ACE-R = Addenbrooke’s Cognitive Examination–revised; bvFTD = behavioral variant frontotemporal dementia; CDR = Clinical Dementia Rating; DAD = Disability Assessment for Dementia.
Values are means. p Values refer to the Kruskal-Wallis test. Q1 = first quartile represents percentile 25; Q2 = second quartile represents percentile 50; Q3 = third quartile represents percentile 75.
a Australia and England ≠ India.
b Australia ≠ Brazil, England ≠ Brazil.
c India ≠ Brazil, India ≠ England.
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Table 2 Characterization of the samples according to levels of disability on the Disability Assessment for Dementia (DAD)
Variables
DAD percentiles
p Value
Mild (76%–100%), n = 13 Moderate (51%–75%), n = 34 Severe (26%–50%), n = 35 Very severe (0%–25%), n = 24
Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3
Age, y 59.00 62.00 68.00 58.00 64.00 72.00 62.00 66.00 72.00 59.00 66.00 73.00 0.425
Sex, n (%)
Male 8 (61.54) 28 (82.35) 17 (48.57) 15 (62.50)
Female 5 (38.46) 6 (17.65) 18 (51.43) 9 (37.50) 0.034a
Education, y 10.50 12.00 13.00 7.00 10.00 13.00 9.00 11.00 15.00 9.00 11.50 15.00 0.134
ACE-R (max score 100) 62.00 79.00 86.00 63.00 73.50 82.00 51.00 65.50 81.00 11.00 40.00 62.00 <0.001b
NPI
Agitation/aggression 0.00 0.00 1.00 0.00 0.00 3.00 0.00 1.00 4.00 0.00 0.00 2.00 0.425
Euphoria 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.478
Apathy 0.00 1.00 6.00 2.00 4.00 8.00 3.00 4.00 8.00 2.50 6.00 12.00 0.089
Disinhibition 0.00 0.00 0.00 0.00 1.00 3.00 0.00 2.00 4.00 0.00 0.50 2.00 0.189
Irritability 0.00 1.00 4.00 0.00 0.00 4.00 0.00 0.00 4.00 0.00 0.00 2.00 0.894
Aberrant motor behavior 0.00 0.00 6.00 0.00 0.00 6.00 0.00 0.00 6.00 0.00 6.00 10.50 0.143
Abbreviations: ACE-R = Addenbrooke’s Cognitive Examination–revised; bvFTD = behavioral variant frontotemporal dementia; NPI = Neuropsychiatric Inventory.
Values are means. p Values refer to the Kruskal-Wallis test. Q1 = first quartile represents percentile 25; Q2 = second quartile represents percentile 50; Q3 = third quartile represents percentile 75.
a Severe ≠ very severe, moderate, mild.
b Very severe ≠ severe, moderate, mild.
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Discussion
This multicenter study conﬁrmed the disabling nature of
bvFTD, and demonstrated the key contributors to level of
functional impairment were apathy and level of overall cog-
nition. Critical decline in global cognition (as measured by
the ACE-R) and increased apathy were relevant to decline on
ADLs overall, whereas decline in cognition had a strong in-
ﬂuence on IADL scores. Factors underlying performance in
BADLs remain unclear.
General cognition appears to be the major factor underlying
disability in bvFTD.1 Our ﬁndings diﬀer from other studies
where apathy was a major factor across ADLs in
bvFTD.1,11-22 Diﬀerences in ﬁndings may reﬂect the larger
sample size used in this study.
Even though general cognitive scores seem to plateau in the
ﬁrst 3 functional stages of bvFTD (mild, moderate, and se-
vere as per DAD scores), the ACE-R was the main key
contributor to the model explaining disability, demonstrating
the role of global cognition in function. Present results
reaﬃrm that deﬁcits in executive or global cognitive functions
are associated with ADL impairment in bvFTD.1,6,23 Future
studies should address this interaction of function and cog-
nitive scores in more detail, bearing in mind the diﬃculties in
applying current standardized neuropsychological tests in
bvFTD. Novel techniques to evaluate cognitive function
would be especially welcome.
Another implication of the complex interaction of function
and cognition in bvFTD is that people may appear, at face
value, to be functioning well based on their cognitive scores,
while in reality they are severely disabled and dependent on
others at home.6,24,25 In addition, it is clear that cognition
only partly explains the variance in functional scores. In fact,
there seems to be a large amount of variability in daily
functioning (especially BADLs) that is not reﬂected in
cognitive status or measurable behaviors (e.g., NPI scores),
and remains to be investigated. Our ﬁndings demonstrate the
need for a multifaceted approach in assessing patients with
bvFTD for the determination of appropriate clinical and
social care, especially as disease progresses and BADL im-
pairment becomes even more pronounced.
Results from this study havemajor implications for patient care,
as they suggest that to facilitate ADL engagement patients with
bvFTD may need cognitive cues as well as strong support to
compensate for their lack of motivation throughout the disease.
In otherwords, patients with bvFTDmay need to have complex
tasks simpliﬁed and broken into steps to reduce cognitive
demands and they may beneﬁt from intense reinforcement
contingencies to improve motivation. Strategies to enhance
reward may also prove useful in this patient population. Such
approaches remain to be conﬁrmed in future trials, but pre-
liminary case study results suggest these could in fact work in
FTD,22 as shown in general dementia.26
In addition, pharmacologic treatment to reduce apathy may
also have a positive inﬂuence on overall ADL performance,
but it remains to be investigated. A key strength of this study
is the compilation of functional data from international
specialist FTD centers across diﬀerent continents, which also
enabled the analyses on a considerable sample size in FTD
Figure General cognitive scores (Addenbrooke’s Cognitive Examination–revised [ACE-R]) and apathy scores (Neuropsy-
chiatric Inventory [NPI]) for each level of functional impairment (Disability Assessment for Dementia [DAD])
(A) General cognitive scores (ACE-R) and (B) apathy scores (NPI) for each level of functional impairment (DAD).Mild,moderate, severe, and very severe. *Mean
of the very severe group was lower than the mean of the other groups in the ACE-R (p < 0.001).
A key strength of this study is the
compilation of functional data from
international specialist FTD centers
across different continents.
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studies, allowing for greater generalization of the results.
Present ﬁndings seem to suggest that regardless of culture-
speciﬁc factors, cognitive deﬁcits and apathy contribute to
functional deﬁcits overall.
Limitations in this study include the secondary datanatureof the
analyses as it did not allow for a priori package training of all
assessments. Nevertheless, DAD data were collected primarily
by the same person (E.M.) across the United Kingdom and
Australia, who also provided training for the Indian group,
limiting some of the potential rater bias. A potential recruitment
bias was that the study arm in Brazil recruited only patients with
bvFTD who were relatively early in the disease, but this may
have been balanced out by the amalgamation of data from other
centers. In addition, a larger sample size would have given the
study more power, given the large amount of variance in the
data, particularly in the NPI.
Our results have shown that in addition to cognitive deﬁcits,
apathy is also an important factor underlying disability in
bvFTD. Interventions targeting reduction of disability in
bvFTD and psychoeducational programs for family and paid
carers should strongly take the above factors into consider-
ation for greater eﬃcacy.
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